KOD News and Press, Kodiak Sciences Inc From 07/24/23

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program PR Newswire PALO ALTO, Calif. , July 24, 2023 ...

2023-07-24 02:54:50 ET Summary Kodiak Sciences shows improved financial performance in Q1 2023, and it's actively developing treatments for prevalent retinal diseases. Kodiak's primary candidate, tarcocimab, is undergoing several clinical trials, aiming to provide a potent anti-VE...

2023-07-12 17:31:16 ET Gainers: Evolus ( NASDAQ: EOLS ) +5% . Omega Therapeutics ( OMGA ) +5% . Kodiak Sciences ( KOD ) +4% . Amazon ( AMZN ) +4% . Cara Therapeutics ( CARA ) +3% . Losers: ViaSat ( VSAT ) -7% ...

2023-07-07 10:15:03 ET Summary Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. The company’s approach to AAV delivery could change the industry, but resul...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

Kodiak Sciences to Present at Upcoming Investor Conferences PR Newswire PALO ALTO, Calif. , May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

Kodiak Sciences Inc. (NASDAQ: KOD) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 14.21% on the day to $6.75. Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commerciali...

2023-05-15 17:40:32 ET Kodiak Sciences ( NASDAQ: KOD ) has filed for a $350M mixed shelf securities offering. The filing does not necessarily indicate that a sale has begun or will occur in the future. The company intends to use the proceeds for working capital, capital ex...

2023-05-15 16:57:03 ET Kodiak Sciences press release ( NASDAQ: KOD ): Q1 GAAP EPS of -$1.35. Kodiak ended the first quarter of 2023 with $421.2 million of cash, cash equivalents and marketable securities. For further details see: Kodiak Sciences GAAP EPS of -...

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and com...